Merck (MRK) Shares Repurchased (2010 - 2026)
Merck (MRK) reported Shares Repurchased of $874.0 million for Q1 2026, down 24.91% year-over-year from $1.2 billion in Q1 2025, and down 30.19% quarter-over-quarter from $1.3 billion in Q4 2025.
Merck (MRK) Shares Repurchased (2010 - 2026) Analysis & Trends
Merck (MRK) has 16 years of Shares Repurchased data on file, last reported at $874.0 million in Q1 2026.
- Shares Repurchased for Q1 2026 came in at $874.0 million, down 24.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 104.17% YoY), and the FY2025 annual result was $5.1 billion, up 289.28% from the prior year.
- Shares Repurchased fell to $874.0 million in Q1 2026 per MRK's latest filing, from $1.3 billion in the prior quarter.
- Over five years, Shares Repurchased peaked at $1.3 billion in Q2 2025 and troughed at $122.0 million in Q1 2024.
- A 4-year average of $662.3 million and a median of $466.0 million in 2023 frame the typical range for Shares Repurchased.
- The sharpest annual moves came in 2024 and 2025: Shares Repurchased dropped 25.74% in 2024, then surged 854.1% in 2025.
- A 4-year view of Shares Repurchased shows it stood at $393.0 million in 2023, then grew by 24.43% to $489.0 million in 2024, then surged by 156.03% to $1.3 billion in 2025, then sank by 30.19% to $874.0 million in 2026.
- Business Quant data shows MRK's Shares Repurchased at $874.0 million in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -439.51 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 2.36 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 4.03 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.49 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 874.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 419.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 874.00 Mn |
| Mar 31, 2026 | 874.00 Mn |
| Dec 31, 2025 | 1.25 Bn |
| Dec 31, 2025 | 1.25 Bn |
| Sep 30, 2025 | 1.32 Bn |
| Sep 30, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.35 Bn |
| Mar 31, 2025 | 1.16 Bn |
| Mar 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 489.00 Mn |
| Dec 31, 2024 | 489.00 Mn |
| Sep 30, 2024 | 444.00 Mn |
| Sep 30, 2024 | 444.00 Mn |
| Jun 30, 2024 | 251.00 Mn |
| Jun 30, 2024 | 251.00 Mn |
| Mar 31, 2024 | 122.00 Mn |
| Mar 31, 2024 | 122.00 Mn |
| Dec 31, 2023 | 393.00 Mn |
| Dec 31, 2023 | 393.00 Mn |